Mitsuyama Keiichi, Tsuruta Kozo, Takedatsu Hidetoshi, Yoshioka Shinichiro, Morita Masaru, Niwa Mikio, Matsumoto Satoshi
Inflammatory Bowel Disease Center, Kurume University Hospital, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan.
Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan.
J Clin Med. 2020 Nov 11;9(11):3630. doi: 10.3390/jcm9113630.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the global coronavirus disease 2019 (COVID-19) outbreak. Along with the respiratory tract, the gastrointestinal (GI) tract is one of the main extra-pulmonary targets of SARS-CoV-2 with respect to symptom occurrence and is a potential route for virus transmission, most likely due to the presence of angiotensin-converting enzyme 2. Therefore, understanding the mechanisms of GI injury is crucial for a harmonized therapeutic strategy against COVID-19. This review summarizes the current evidence for the clinical features of and possible pathogenic mechanisms leading to GI injury in COVID-19.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是2019年全球冠状病毒病（COVID-19）疫情的病原体。除呼吸道外，胃肠道是SARS-CoV-2在症状出现方面的主要肺外靶器官之一，并且是病毒传播的潜在途径，这很可能是由于血管紧张素转换酶2的存在。因此，了解胃肠道损伤机制对于制定统一的COVID-19治疗策略至关重要。本综述总结了目前关于COVID-19胃肠道损伤临床特征及可能致病机制的证据。
